Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 6/20 | 0.64 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 10/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470567 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL15025485 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL15025556 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12629349 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL13621431 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12492350 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12410315 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL3471272 | 1.00 | SLC1A1 (0.64) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL13224535 | 0.86 | SLC1A1 (0.54) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL12900234 | 0.86 | SLC1A1 (0.54) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | GLUL, QPCT, GFPT1 | SLC1A1 15/4885SLC1A2 4/4885SLC1A3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.